Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical company advancing tecarfarin, a novel oral anticoagulant targeting critical unmet needs in cardiovascular care. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely, verified information about tecarfarin's progress through Phase 3 trials and its potential applications for LVAD patients and rare cardiovascular conditions. Our news collection includes press releases on FDA designations, trial results, and collaborations with industry leaders in cardiac device therapy.
Key updates cover tecarfarin's unique metabolic profile designed to reduce drug interactions, its Orphan Drug status for specific indications, and progress toward addressing anticoagulation challenges in renal-impaired patients. All content is curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Cadrenal Therapeutics' official announcements, including financial reports, clinical data publications, and partnership developments. Check regularly for updates on this innovative therapy's journey through late-stage clinical evaluation.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has provided a corporate update alongside its Annual Report for FY 2022. The company focuses on developing tecarfarin, a novel therapy with orphan drug and Fast Track designations from the FDA, aimed at preventing systemic thromboembolism in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib). Key highlights include the FDA's Fast Track designation for tecarfarin, the formation of a Scientific Advisory Board, and the successful completion of an IPO raising $7 million. A Phase 3 clinical trial, ACTOR-AF, is planned with the potential to address a significant market opportunity worth up to $1 billion annually if approved.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical firm, is advancing tecarfarin, a new therapy aimed at preventing systemic thromboembolism in patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib). During March, recognized as National Kidney Month, the company highlights the urgent need for effective treatments for this underserved group, which includes over 150,000 ESRD patients also suffering from AFib. With total Medicare spending for ESRD patients hitting $51 billion in 2019, tecarfarin's potential to reduce risks of stroke and mortality is significant. Currently, a Phase 3 clinical trial is being planned as the FDA shows interest.
Cadrenal Therapeutics (Nasdaq: CVKD) has announced that its CEO, Quang Pham, will ring the Nasdaq Stock Market closing bell on February 8, 2023. This event commemorates the company's recent IPO and the Fast Track designation granted by the FDA for tecarfarin, a novel therapy aimed at preventing cardiac-origin blood clots in patients with end-stage renal disease and atrial fibrillation. Tecarfarin has undergone 11 clinical trials and demonstrated good tolerance among participants. The ceremony is set to be broadcast live at 3:45 p.m. ET.
FAQ
What is the current stock price of Cadrenal Therape (CVKD)?
What is the market cap of Cadrenal Therape (CVKD)?
